Alejandra Abeledo-Machado

Alejandra Abeledo-Machado

Auto-generated profile, based on publicly available information

Alejandra Abeledo-Machado

Instituto de Biología y Medicina Experimental (IBYME), CONICET, Buenos Aires, Argentina

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 June 2018 in Journal of Neuroendocrinology
Verified
Journal Article
Open access
PDF file
MCMaria Andrea Camilletti
Maria Andrea Camilletti
JFJimena Ferraris
Jimena Ferraris
AAAlejandra Abeledo‐Machado
Alejandra Abeledo‐Machado
ACAubrey Converse
Aubrey Converse
EFE. Y. Faraoni
E. Y. Faraoni
GDGraciela Díaz‐Torga
Graciela Díaz‐Torga
The membrane progesterone receptors (mPRα, mPRβ, mPRγ, mPRδ and mPRε) are known to mediate rapid nongenomic progesterone functions in different cell types. However, the functions of these receptors in the pituitary have not been reported to date. In the present study, we show that the expression of mPRα was the highest among the mPRs in the rat anterior pituitary gland. Immunostaining of mPRα was detected in somatotrophs, gonadotrophs and lactotrophs. Interestingly, 63% of mPRα‐positive cells within the pituitary were lactotrophs, suggesting that mPRα is involved in controlling prolactin (PRL) secretion in the pituitary. To test this hypothesis, rat pituitaries were incubated (1 hour) with either progesterone (P4) or the mPRα‐specific agonist Org OD 02‐0. PRL secretion was then measured by radioimmunoassay. The results of this experiment revealed that both P4 and Org OD 02‐0 decreased PRL secretion. Moreover, the results from the GH3 cell line (CCL‐82.1) showed that P4 and Org OD 02‐0 inhibited PRL release, although the nuclear PR agonist R5020 was ineffective. Our investigation of the cellular mechanisms behind mPRα activity indicated that both P4 and Org OD 02‐0 decreased cAMP accumulation, whereas R5020 was ineffective. In addition, the Org OD 02‐0‐effect on PRL release was blocked by pretreatment with pertussis toxin, an inhibitor of Go/Gi proteins. Because transforming growth factor (TGF)β1 is a potent inhibitor of PRL secretion in lactotrophs, we lastly evaluated whether TGFβ1 was activated by progesterone and whether this effect was mediated by mPRα. Our results showed that P4 and Org OD 02‐0, but not R5020, increased active TGFβ1 levels. This effect was not observed when cells were transfected with mPRα‐small interfering RNA. Taken together, these data provide new evidence suggesting that mPRα mediates the progesterone inhibitory effect on PRL secretion through both decreases in cAMP levels and activation of TGFβ1 in the lactotroph population.

1 February 2019 in Journal of Endocrinology
Verified
Journal Article
Closed access
PDF file
MCMaria Andrea Camilletti
Maria Andrea Camilletti
AAAlejandra Abeledo-Machado
Alejandra Abeledo-Machado
JFJimena Ferraris
Jimena Ferraris
PPPablo A Pérez
Pablo A Pérez
EFErika Yanil Faraoni
Erika Yanil Faraoni
GDGraciela Díaz-Torga
Graciela Díaz-Torga
Ovarian steroids control a variety of physiological functions. They exert actions through classical nuclear steroid receptors, but rapid non-genomic actions through specific membrane steroid receptors have been also described. In this study, we demonstrate that the G-protein-coupled estrogen receptor (GPER) is expressed in the rat pituitary gland and, at a high level, in the lactotroph population. Our results revealed that ~40% of the anterior pituitary cells are GPER positive and ~35% of the lactotrophs are GPER positive. By immunocytochemical and immuno-electron-microscopy studies, we demonstrated that GPER is localized in the plasmatic membrane but is also associated to the endoplasmic reticulum in rat lactotrophs. Moreover, we found that local Gper expression is regulated negatively by 17β-estradiol (E2) and progesterone (P4) and fluctuates during the estrus cycle, being minimal in proestrus. Interestingly, lack of ovarian steroids after an ovariectomy (OVX) significantly increased pituitary GPER expression specifically in the three morphologically different subtypes of lactotrophs. We found a rapid estradiol stimulatory effect on PRL secretion mediated by GPER, both in vitro and ex vivo , using a GPER agonist G1, and this effect was prevented by the GPER antagonist G36, demonstrating a novel role for this receptor. Then, the increased pituitary GPER expression after OVX could lead to alterations in the pituitary function as all three lactotroph subtypes are target of GPER ligand and could be involved in the PRL secretion mediated by GPER. Therefore, it should be taken into consideration in the response of the gland to an eventual hormone replacement therapy.

1 March 2017 in Journal of Endocrinology
Verified
Journal Article
Closed access
PDF file
EFErika Y Faraoni
Erika Y Faraoni
MCMaria Andrea Camilletti
Maria Andrea Camilletti
AAAlejandra Abeledo-Machado
Alejandra Abeledo-Machado
LRLaura D Ratner
Laura D Ratner
FFFernanda De Fino
Fernanda De Fino
GDGraciela Díaz-Torga
Graciela Díaz-Torga
Female transgenic mice that overexpress the human chorionic gonadotrophin β subunit (hCGβ+) develop prolactinomas, whereas hCGβ+ males do not. The high levels of circulating hCG induce massive luteinization in the ovary of hCGβ+ females, and progesterone becomes the primary steroid hormone produced, but estradiol remains at physiological level. The involvement of high levels of progesterone in lactotroph proliferation is not clearly understood; hence, the pathogenesis of prolactinomas in hCGβ+ females remains unclear. TGFβ1 is an inhibitor of lactotroph function, and the reduced TGFβ1 activity found in prolactinomas has been proposed to be involved in tumor development. The aim of the present work was to study the role of TGFβ1 in the gender-specific development of prolactinomas in hCGβ+ mice. We compared the expression of different components of the pituitary TGFβ1 system in males and females in this model. We found reduced TGFβ1 levels, reduced expression of TGFβ1 target genes, TGFβ1 receptors,Ltbp1,Smad4andSmad7in hCGβ+ female pituitaries. However, no differences were found between the transgenic and wild-type male pituitaries. We postulate that decreased pituitary TGFβ1 activity in hCGβ+ females is involved in the development of prolactinomas. In fact, we demonstrated that anin vivotreatment carried out for increasing pituitary TGFβ1 activity, was successful in reducing the prolactinoma development, and the hyperprolactinemia in hCGβ+ females. Moreover, the stronger TGFβ1 system found in males could protect them from excessive lactotroph proliferation. Sex differences in the regulation of the pituitary TGFβ1 system could explain gender differences in the incidence of prolactinoma.

1 December 2019 in Steroids
Verified
Journal Article
Closed access
MCMaria Andrea Camilletti
Maria Andrea Camilletti
AAAlejandra Abeledo-Machado
Alejandra Abeledo-Machado
EFErika Y. Faraoni
Erika Y. Faraoni
PTPeter Thomas
Peter Thomas
GDGraciela Díaz-Torga
Graciela Díaz-Torga

1 May 2019 in Endocrine-Related Cancer
Verified
Journal Article
Closed access
PDF file
MCMaria Andrea Camilletti
Maria Andrea Camilletti
AAAlejandra Abeledo-Machado
Alejandra Abeledo-Machado
PPPablo A Perez
Pablo A Perez
EFErika Y Faraoni
Erika Y Faraoni
FFFernanda De Fino
Fernanda De Fino
GDGraciela Díaz-Torga
Graciela Díaz-Torga
Membrane progesterone receptors are known to mediate rapid nongenomic progesterone effects in different cell types. Recent evidence revealed that mPRα is highly expressed in the rat pituitary, being primarily localized in lactotrophs, acting as an intermediary of P4-inhibitory actions on prolactin secretion. The role of mPRs in prolactinoma development remains unclear. We hypothesize that mPR agonists represent a novel tool for hyperprolactinemia treatment. To this end, pituitary expression of mPRs was studied in three animal models of prolactinoma. Expression of mPRs and nuclear receptor was significantly decreased in tumoral pituitaries compared to normal ones. However, the relative proportion of mPRα and mPRβ was highly increased in prolactinomas. Interestingly, the selective mPR agonist (Org OD 02-0) significantly inhibited PRL release in both normal and tumoral pituitary explants, displaying a more pronounced effect in tumoral tissues. As P4 also regulates PRL secretion indirectly, by acting on dopaminergic neurons, we studied mPR involvement in this effect. We found that the hypothalamus has a high expression of mPRs. Interestingly, both P4 and OrgOD 02-0 increased dopamine release in hypothalamus explants. Moreover, in an in vivo treatment, that allows both, pituitary and hypothalamus actions, the mPR agonist strongly reduced the hyperprolactinemia in transgenic females carrying prolactinoma. Finally, we also found and interesting gender difference: males express higher levels of pituitary mPRα/β, a sex that does not develop prolactinoma in these mice models. Taken together, these findings suggest mPRs activation could represent a novel tool for hyperprolactinemic patients, especially those that present resistance to dopaminergic drugs.

1 July 2018 in Frontiers in Neuroendocrinology
Verified
Journal Article
Open access
MRM. Victoria Recouvreux
M. Victoria Recouvreux
EFErika Y. Faraoni
Erika Y. Faraoni
MCMaria Andrea Camilletti
Maria Andrea Camilletti
LRLaura Ratner
Laura Ratner
AAAlejandra Abeledo-Machado
Alejandra Abeledo-Machado
GDGraciela Díaz-Torga
Graciela Díaz-Torga
Prolactinomas are the most frequent functioning pituitary adenomas, and sex differences in tumor size, behavior and incidence have been described. These differences have been associated with earlier diagnosis in woman, as well as with serum estradiol levels. Experimental models of prolactinomas in rodents also show a higher incidence in females, and recent findings suggest that gender differences in the transforming growth factor beta 1 (TGFβ1) system might be involved in the sex-specific development of prolactinomas in these models. The aim of this review is to summarize the literature supporting the important role of TGFβ1 as a local modulator of pituitary lactotroph function and to provide recent evidence for TGFβ1 involvement in the sex differences found in prolactinoma development in animal models.